Market News & Trends
UPM Biomedicals Launches FibGel, World’s First Injectable Nanocellulose Hydrogel for Medical Devices
UPM Biomedicals recently announced the launch of FibGel, a natural injectable hydrogel for permanent implantable medical devices. FibGel is a nanofibrillar cellulose hydrogel made from…
GRI Bio Raises $13.9 Million in Gross Proceeds Since the Beginning of 2024
GRI Bio, Inc. recently announced it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 762,236 shares…
BirchBioMed Receives Health Canada Green Light to Start the Last Stage of its Groundbreaking Clinical Program to Minimize Scarring From Burns
BirchBioMed recently announced the authorization from Health Canada to conduct its Phase 2/3 randomized clinical trial of a naturally based compound, FS2, at multiple centers…
Novadip Reports Promising Interim Results From First-in-Human Proof-of-Concept Trial of New Game Changer in Bone Field
Novadip Biosciences recently announced positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures…
Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION Platform
Avacta Group plc recently announced the addition of two novel preclinical oncology assets, AVA6103 and AVA7100, to its pipeline of pre|CISION-enabled drug conjugates. Avacta is…
Immutep Announces First-in-Human Phase 1 Study of IMP761 Progresses to Dose Escalation Portion of Trial
Immutep Limited recently announced the first part (Part A, single dose) of the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761 has been fully recruited…
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Immune Regulator for Treatment of Acute Respiratory Distress Syndrome
BioAegis Therapeutics recently announced the first patient has been enrolled in the company’s Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress…
Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications
Biognosys recently announced its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany. The company…
mRNA Licensing Agreements Surge 800% in Value as Confidence Grows Beyond Vaccines
Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800% increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success…
Cullinan Therapeutics Receives IND Clearance for CLN-978 Administered Subcutaneously in Patients With Moderate-to-Severe Systemic Lupus Erythematosus
Cullinan Therapeutics, Inc. recently announced the US FDA cleared the Company’s Investigational New Drug (IND) Application for CLN-978 and its global Phase 1 clinical trial…
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients With Neuropathic Corneal Pain
OKYO Pharma Limited recently announced that screening and recruitment of patients has started for a Phase 2 trial of OK-101 to treat NCP. The Phase…
IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IGNX001 in Peanut Allergy
IgGenix, Inc. recently announced the first patient dosed in its ACCELERATE Peanut Phase 1 clinical trial. The trial aims to evaluate IGNX001, a novel therapeutic…
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Ltd. recently announced positive proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD). WVE-006 is…
Cellular Origins & Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell & Gene Therapy Manufacturing
Cellular Origins and Fresenius Kabi, an operating company of Fresenius, recently announced they have signed a development agreement that leverages each company’s expertise in cell…
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T Cell Activity & Reduce Important Inflammatory & Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary…
ProductLife Group Acquires Halloran to Further Expand Its Global Reach & Capabilities to Support Development of New Therapies
ProductLife Group (PLG) recently announced the acquisition of Halloran Consulting Group, further positioning PLG as a leading global provider of comprehensive healthcare services. Utilizing its 1,900+…
Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)
Lonza recently announced it has enhanced its drug product services offering by adding a new facility for quality control and bioanalytics at its DPS site…
Lipella Pharmaceuticals Announces Patent Allowance for Innovative Liposomal Drug Delivery Platform
Lipella Pharmaceuticals Inc. recently announced the receipt of a notice of allowance from the US Patent and Trademark Office (USPTO) for its proprietary liposomal drug…
Bespak & H&T Presspart Announce Availability of GMP Pilot Line for Low GWP pMDIs
Bespak, a specialist inhalation contract development and manufacturing organization (CDMO), and H&T Presspart, a market leader in the development, manufacturing and supply of inhaled drug…
Impact BioMedical Inc. Announces Issuance of Patent for Linebacker Technology Targeting Inflammatory Disease
Impact BioMedical Inc. recently announced a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 titled…
